216
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Cytomegalovirus colitis complicating ulcerative colitis treated with adalimumab

, , , , &
Pages 509-510 | Received 24 Dec 2009, Accepted 28 Dec 2009, Published online: 23 Jan 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Davide Fiore Bavaro, Deborah Fiordelisi, Gioacchino Angarano, Laura Monno & Annalisa Saracino. (2020) Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. Expert Opinion on Drug Safety 19:7, pages 817-842.
Read now
Gabriele Bianchi Porro. (2010) EDITORIAL. Scandinavian Journal of Gastroenterology 45:4, pages 387-388.
Read now

Articles from other publishers (4)

Barathy Rani Ramasamy, Patrick Charles, Douglas Johnson & Albert Frauman. (2017) Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab. BMJ Case Reports, pages bcr-2017-220184.
Crossref
Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo & Sami Hoque. (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment 20:39, pages 1-326.
Crossref
Phillip D. Smith, Masako Shimamura, Lois C. Musgrove, Evida A. Dennis, Diane Bimczok, Lea Novak, Mary Ballestas, Anne Fenton, Satya Dandekar, William J. Britt & Lesley E. Smythies. (2014) Cytomegalovirus Enhances Macrophage TLR Expression and MyD88-Mediated Signal Transduction To Potentiate Inducible Inflammatory Responses. The Journal of Immunology 193:11, pages 5604-5612.
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:11, pages i-xii.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.